Organisation paid for research Program year 2025 Source: CMS Open Payments

Revival Research

Neither a doctor nor a teaching hospital

Research payments

$1,806,413

208 payments

Through program year 2025, Revival Research is reported as receiving $1,806,413 in research payments, across 208 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$274,404	27
2024	Research	$471,510	14
2023	Research	$10,495	2
2022	Research	$244,978	15
2021	Research	$538,354	114
2020	Research	$114,990	14
2019	Research	$151,682	22

Breakdown

Who paid Research payments · program years 2019–2025

Takeda Pharmaceuticals U.S.A., Inc. $726,113 39 payments
Amgen Inc. $651,901 13 payments
LEO Pharma AS $220,749 35 payments
Moderna TX, Inc. $168,440 8 payments
GlaxoSmithKline, LLC. $26,550 12 payments
Novo Nordisk AS $10,165 100 payments
Pfizer Inc. $2,495 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $630,327 27 payments
ABP 654 P3 PsO Study $449,161 4 payments
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $140,639 5 payments
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $87,786 11 payments
ABP 654 Phase 3 PsO Study $80,605 4 payments
Tralokinumab Drug Interaction Trail $71,492 8 payments
P3 switching study PK; plaque psoriasis $68,571 3 payments
Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $60,622 12 payments
Random DB P3 Study in adult subjects with moderate to severe plaque psoriasis $53,564 2 payments
Tralokinumab Vaccine Response Time $43,385 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.